Google NewsWhy PolyNovo Fell Even As Sales Rose - Simply Wall Street
Why PolyNovo Fell Even As Sales Rose Simply Wall Street
PNV
Health Care Equipment & Services
Polynovo
- Short interest
- 7.27%
- −0.72 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 50.2M
- Shares on issue
- 690.843M
Polynovo (PNV) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineCan PolyNovo (ASX:PNV) Keep Its Wound-Care Growth Running?
Highlights The burns and wound-care device maker has swung to positive free cash flow A new manufacturing facility is built and a fresh product launch is close US reimbursement and seasonal burns volumes remain the headwinds PolyNovo (ASX:PNV), the Melbourne-based maker of the NovoSorb synthetic skin-replacement technology, is trying to prove that a record year of sales and a first meaningful run of positive free cash flow mark a durable shift rather than a lucky stretch. The stock is one of ...
ASXPolyNovo Notice of Annual General Meeting
other announcement
Dean Phizacklea and Andrew Price Appointed to PNV Board
other announcement
PolyNovo FY26 Corporate Governance Statement
other announcement
Polynovo (ASX:PNV) Comes Under Pressure - What Could Drive the Next Move? - Kalkine
Polynovo (ASX:PNV) Comes Under Pressure - What Could Drive the Next Move? Kalkine
Polynovo Limited (ASX:PNV): Why This Under-the-Radar ASX Stock Could Be One to Watch in September - Kalkine
Polynovo Limited (ASX:PNV): Why This Under-the-Radar ASX Stock Could Be One to Watch in September Kalkine
_08_31_2026_12_20_21_515992.jpg&w=3840&q=65)
Can Value Stocks Shift Around PolyNovo (ASX:PNV)?
Highlights Cash flow screens have flagged the wound care specialist as trading below estimated worth. Its biodegradable polymer technology continues to expand across surgical applications. A volatile share price history has repeatedly detached from operational progress. The latest local-market debate around value stocks has brought PolyNovo (ASX:PNV) back into view, with operating detail carrying more weight than broad sentiment. PolyNovo (ASX:PNV) has resurfaced on screens identifying Austra...
PolyNovo Ltd (ASX:PNV): What's Behind the Wound Care Innovator's Share Price Slide - Kalkine
PolyNovo Ltd (ASX:PNV): What's Behind the Wound Care Innovator's Share Price Slide Kalkine
PolyNovo FY26 Results Presentation Webinar Recording
other announcement
PolyNovo FY26 Results Presentation - Registration Details
other announcement
PolyNovo (ASX:PNV) Advances as Manufacturing Expansion Progresses - Kalkine
PolyNovo (ASX:PNV) Advances as Manufacturing Expansion Progresses Kalkine
A Healthcare Innovator in Focus: What Investors Are Watching Around PolyNovo (ASX:PNV)? - Kalkine
A Healthcare Innovator in Focus: What Investors Are Watching Around PolyNovo (ASX:PNV)? Kalkine
What Is Bringing PolyNovo (ASX:PNV) Into Focus?
Highlights PolyNovo remains closely watched as sector positioning becomes central to its place within smaller-company execution and commercial scaling. The wider category is being shaped by market access, customer concentration, funding flexibility and operating leverage. Operational consistency and clear capital priorities continue defining how organisational progress is assessed. Australia's share market is placing renewed emphasis on business quality as global conditions, funding settings ...
PolyNovo (ASX:PNV) Plunges as Healthcare Stocks Join the Market Retreat - Kalkine
PolyNovo (ASX:PNV) Plunges as Healthcare Stocks Join the Market Retreat Kalkine
Why PolyNovo (ASX:PNV) Stock Is Under Pressure - Kalkine
Why PolyNovo (ASX:PNV) Stock Is Under Pressure Kalkine
Polynovo (ASX:PNV) Falls Back Today — Is the Wound Care Biotech Still a Compelling Long-Term Story? - Kalkine
Polynovo (ASX:PNV) Falls Back Today — Is the Wound Care Biotech Still a Compelling Long-Term Story? Kalkine
PolyNovo posts $150m revenue and positive free cash flow as US sales hit a new record
Melbourne-based medical device company PolyNovo (ASX: PNV) has posted preliminary unaudited group revenue of $150 million for FY26, up 16.1 per cent on the prior year's $129.2 million as its flagship skin regeneration products gained further traction in the United States. The result, disclosed in a trading update lodged with the ASX, repres...
Motley FoolPolyNovo FY26 earnings: Record revenue and cash flow
PolyNovo posts record group revenue, robust cash flow, and surging commercial sales for FY26, with a positive outlook for further growth. The post PolyNovo FY26 earnings: Record revenue and cash flow appeared first on The Motley Fool Australia.
Polynovo (ASX:PNV) Pulls Back — MedTech Innovator Faces Some Selling Pressure - Kalkine
Polynovo (ASX:PNV) Pulls Back — MedTech Innovator Faces Some Selling Pressure Kalkine
PolyNovo (ASX:PNV) Shares Climb as Healthcare Sector Extends Positive Momentum - Kalkine
PolyNovo (ASX:PNV) Shares Climb as Healthcare Sector Extends Positive Momentum Kalkine
Polynovo (ASX:PNV) Drops as Healthcare Growth Stocks Face a Market Pause - Kalkine
Polynovo (ASX:PNV) Drops as Healthcare Growth Stocks Face a Market Pause Kalkine
Why PolyNovo Shares (ASX:PNV) Slumped 5% Today on the ASX - Kalkine
Why PolyNovo Shares (ASX:PNV) Slumped 5% Today on the ASX Kalkine
U.S. Pivotal Trial CSR Finalised and PMA Submission Update
other announcement
PolyNovo (ASX:PNV) Shares Face Pressure Amid Shifting Healthcare Market Sentiment - Kalkine
PolyNovo (ASX:PNV) Shares Face Pressure Amid Shifting Healthcare Market Sentiment Kalkine
Appointment of Dr Marthe DOmbrain as Chief Scientific Offic
other announcement
Initial Director's Interest Notice - Charmaine Gittleson
other announcement
Change of Director's Interest Notice - Robert Douglas
director_dealing announcement
Change of Director's Interest Notice - Andrew Lumsden
director_dealing announcement
Update on fire event at R&D facility - fully insured
other announcement